Statement: There were no depressed patients in either the primary trial or the secondary trial, however there was one suicide attempt in cohort 2 of the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 31/116 (26.72%)   Neutropenia 1/116 (0.86%)   Thrombocytopenia 1/116 (0.86%)   Acute myocardial infarction 1/116 (0.86%)   Myocardial infarction 0/116 (0.00%)   Pericardial effusion 0/116 (0.00%)   Abdominal pain 3/116 (2.59%)   Ascites 1/116 (0.86%)   Diarrhoea 3/116 (2.59%)   Gingival bleeding 1/116 (0.86%)   Intestinal haemorrhage 1/116 (0.86%)   Nausea 2/116 (1.72%) Adverse Events 2:   Total: 24/115 (20.87%)   Neutropenia 1/115 (0.87%)   Thrombocytopenia 0/115 (0.00%)   Acute myocardial infarction 0/115 (0.00%)   Myocardial infarction 1/115 (0.87%)   Pericardial effusion 1/115 (0.87%)   Abdominal pain 0/115 (0.00%)   Ascites 0/115 (0.00%)   Diarrhoea 4/115 (3.48%)   Gingival bleeding 0/115 (0.00%)   Intestinal haemorrhage 0/115 (0.00%)   Nausea 3/115 (2.61%)
Secondary_evidence: Adverse Events 1:   Total: 8/54 (14.81%)   Anaemia 1/54 (1.85%)   Febrile Neutropenia 1/54 (1.85%)   Retinopathy Hypertensive 1/54 (1.85%)   Febrile Infection 1/54 (1.85%)   Postoperative Wound Complication 1/54 (1.85%)   Cardiac Imaging Procedure Abnormal 1/54 (1.85%)   Malignant Melanoma In Situ 1/54 (1.85%)   Suicide Attempt 1/54 (1.85%)   Dyspnoea 1/54 (1.85%)